M&A

LABORIZON

Name: mynth M&A Transaction Multiples Database
Creator: mynth
License: https://mynthcapital.com/privacy

Acquired by

BIOGROUP

FRANCE Health Providers EV [100m EUR - 500m EUR] 07/2020

LABORIZON acquired by BIOGROUP

FRANCE Health Providers EV [100m EUR - 500m EUR] 07/2020

Target

LABORIZON

Acquirer

BIOGROUP

Context

Biogroup acquired Laborizon. This strategic move allowed Biogroup to expand its footprint in Western France (Brittany, Normandy, Centre Val de Loire) and strengthen its position as a French leader alongside Cerba. The deal was finalized despite the COVID-19 pandemic, which underscored the critical nature of medical analysis infrastructure.

LABORIZON, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN discount to the 13.4x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

A major regional medical biology group formed by the merger of five laboratory groups. It operates approx. 100 local sites and 6 technical platforms, serving the Center, Normandy, and Brittany regions.

Ent. Value

Equity Value

Multiples Analysis

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Other operations with LABORIZON

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.